Aclaris Therapeutics logo

Aclaris Therapeutics

ACRS | NASDAQ
Chart Builder DCF Calculator
$3.60
-$0.32 (-8.16%)
At close: Nov 16, 2026, 4:00 PM ET
$3.66
+$0.06 (+1.66%)
After-hours: Nov 16, 2026, 7:30 PM ET
-8.16%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
32.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #720/1021 (Top 71%)

Key Statistics

Market Data

Market Cap $571.8M
1D Range
3.31 3.70
52W Range
2.41 6.54

Valuation (TTM)

PE -6.21
PB 3.43
EV/EBITDA -5.57

Valuation (NTM)

Forward PE N/A
Forward PEG -0.47
Price Target $9.50
Loading financial charts...

Profile

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inf...

Sector Healthcare
Industry Biotechnology
Employees 71
IPO Date Oct 6, 2015
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.12
Beat +25.00%
REV
$1.48M
Beat +16.54%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$9.50
Upside
+163.89%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.